Candidiasis, invasive
diseaseOn this page
Also known as candidiases, invasiveinvasive candidiasesinvasive candidiasis
Summary
Candidiasis, invasive (MONDO:0044067) is a disease and 50 clinical trials. Top therapeutic interventions include caspofungin, fluconazole, and micafungin. A subtype of candidiasis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: Unknown (Europe) [Orphanet-validated]
- Clinical trials: 50
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 100 000 | 2.5 | France | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | candidiasis, invasive |
| Mondo ID | MONDO:0044067 |
| MeSH | D058365 |
| Orphanet | 636945 |
| NCIT | C116813 |
| UMLS | C1609535 |
| MedGen | 296300 |
| GARD | 0025877 |
| Is cancer (heuristic) | no |
Also known as: candidiases, invasive · invasive candidiases · invasive candidiasis
Disease family
This is a subtype of candidiasis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › opportunistic mycosis › candidiasis › candidiasis, invasive
Related subtypes (8): cutaneous candidiasis, esophageal candidiasis, candidal paronychia, neonatal candidiasis, oral candidiasis, candida glabrata infection, congenital candidiasis, disseminated candidiasis
Subtypes (1): candidemia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 7 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Anidulafungin | Phase 3 (in late-stage trials) |
| Caspofungin | Phase 3 (in late-stage trials) |
| Fluconazole | Phase 3 (in late-stage trials) |
| Fosmanogepix | Phase 3 (in late-stage trials) |
| Ibrexafungerp | Phase 3 (in late-stage trials) |
| Micafungin | Phase 3 (in late-stage trials) |
| Voriconazole | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Amphotericin B.
Clinical trials & evidence
Clinical trials
Clinical trials: 50.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 20 |
| PHASE3 | 13 |
| PHASE4 | 7 |
| PHASE2 | 7 |
| PHASE1 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03717623 | PHASE4 | RECRUITING | Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants |
| NCT00520234 | PHASE4 | COMPLETED | Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU) |
| NCT00548262 | PHASE4 | COMPLETED | This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis |
| NCT00670657 | PHASE4 | COMPLETED | CRITIC - Treatment of Candidemia and Invasive Candidiasis |
| NCT02164890 | PHASE4 | COMPLETED | Pharmacokinetics of Micafungin in Patients of Intensive Care Units |
| NCT03906916 | PHASE4 | TERMINATED | Comparison of Two Diagnostic Tests in Patients With Suspected Invasive Candidiasis in Internal Medicine Wards and Who Are Currently Timely Treated With Micafungin |
| NCT05496725 | PHASE4 | COMPLETED | Evaluate Bioequivalence of Micafungin (50mg/Vial) |
| NCT05421858 | PHASE3 | RECRUITING | A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. |
| NCT00189709 | PHASE3 | COMPLETED | Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia |
| NCT00250432 | PHASE3 | COMPLETED | A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED) |
| NCT00413218 | PHASE3 | COMPLETED | Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections |
| NCT00689338 | PHASE3 | COMPLETED | Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study |
| NCT01773876 | PHASE3 | COMPLETED | Empirical Antifungal Treatment in ICUS |
| NCT03059992 | PHASE3 | COMPLETED | Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment |
| NCT03363841 | PHASE3 | COMPLETED | Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) |
| NCT03667690 | PHASE3 | COMPLETED | Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis |
| NCT04368559 | PHASE3 | COMPLETED | Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation |
| NCT05178862 | PHASE3 | TERMINATED | A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole |
| NCT05707832 | PHASE3 | COMPLETED | A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus |
| NCT05848492 | PHASE3 | COMPLETED | Efficacy of Prophylactic Fluconazole Therapy in Preterm and Very Low Birth Weight Neonates in Preventing Invasive Fungal Infection. |
| NCT01045798 | PHASE2 | TERMINATED | Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067) |
| NCT01165320 | PHASE2 | COMPLETED | A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074) |
| NCT01945281 | PHASE2 | TERMINATED | Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064) |
| NCT02244606 | PHASE2 | COMPLETED | Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis |
| NCT02734862 | PHASE2 | COMPLETED | CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension |
| NCT04148287 | PHASE2 | COMPLETED | An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris |
| NCT04225195 | PHASE2 | UNKNOWN | Amphotericin B Cholesteryl Sulfate Complex for Injection(ABCD) in the Treatment of Invasive Candidiasis and Invasive Aspergillosis |
| NCT00607763 | PHASE1 | COMPLETED | Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug |
| NCT00608335 | PHASE1 | COMPLETED | Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug |
| NCT01666769 | PHASE1 | COMPLETED | Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation |
| NCT03450005 | Not specified | RECRUITING | ECMM Candida Registry - CandiReg |
| NCT05763251 | Not specified | RECRUITING | Comparison of Uncomplicated Candidemia Therapy Duration in Children |
| NCT06456151 | Not specified | RECRUITING | Invasive Candidiasis in Critical Care |
| NCT00672841 | Not specified | COMPLETED | β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients |
| NCT00786903 | Not specified | COMPLETED | Candida Spp. in the Lower Respiratory Tract: Harmless Residents or Pathogen? |
| NCT01047267 | Not specified | COMPLETED | Pharmacokinetics of Anidulafungin on Intensive Care Unit (ICU) |
| NCT01213823 | Not specified | TERMINATED | Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins |
| NCT01438216 | Not specified | UNKNOWN | Anidulafungin Pharmacokinetics in Intensive Care Unit Patients |
| NCT01490684 | Not specified | COMPLETED | Invasive Candidiasis in Saudi ICUs |
| NCT01716988 | Not specified | COMPLETED | Pharmacokinetics of Micafungin in Critically Ill Patients |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CASPOFUNGIN | 4 | 9 |
| FLUCONAZOLE | 4 | 9 |
| MICAFUNGIN | 4 | 9 |
| IBREXAFUNGERP | 4 | 4 |
| REZAFUNGIN | 4 | 3 |
| VORICONAZOLE | 4 | 3 |
| AMPHOTERICIN B | 4 | 2 |
| ANIDULAFUNGIN | 4 | 2 |
| POSACONAZOLE | 4 | 2 |
| SODIUM CHLORIDE | 4 | 2 |
| FOSMANOGEPIX | 3 | 2 |
| ISAVUCONAZOLE | 3 | 1 |
| CHEMBL4750941 | 0 | 7 |
| CHEMBL499808 | 0 | 7 |
| CHEMBL3760049 | 0 | 2 |
| CHEMBL4743205 | 0 | 2 |
| CHEMBL4764856 | 0 | 1 |
| CHEMBL6067678 | 0 | 1 |